Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.32 |
| ▸ | NOS2 | P35228 | 3/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22724 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL11230 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL5497317 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL2074366 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL308940 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL296805 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL10943225 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL307406 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL9869925 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR | |
| SCHEMBL9870407 | 1.00 | ALDH1A1 (1.00) | ALDH1A1THRBMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | ALDH1A1 2325/4885THRB 3646/4885MEN1 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.